Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum
Use
This test is used as an initial screening tool for the diagnosis of bullous pemphigoid and its variants. It is performed using the Enzyme-Linked Immunosorbent Assay (ELISA) to detect serum IgG antibodies against BP180 and BP230 antigens, which are common in patients with bullous pemphigoid. The test helps in complementing the standard serum test of indirect immunofluorescence using primate esophagus substrate and primate salt-split skin substrate.
Special Instructions
Not provided.
Limitations
The assay is not validated for use on specimen types other than serum or on pediatric patients. It serves as an aid in diagnosis and should not be interpreted as conclusive on its own. False positives can occur, as seen with 11% of patients with other autoimmune blistering disorders showing BP180 autoantibodies.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 92671-7 - BMZ BP180 + BP230 IgG Pnl SerPl
- 53842-1 - BMZ BP180 IgG SerPl-aCnc
- 53843-9 - BMZ BP230 IgG SerPl-aCnc
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Collect in a red top tube, centrifuge, and aliquot serum into a plastic vial.
Causes for Rejection
Not specified with causes for rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 30 days |